Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The company which focuses on developing psilocybin-based medicines for illnesses with unmet medical needs announced the 2 patents via press release. The first #63/405,786 is a patent application for the use of psilocybin to treat patients with fibromyalgia while the other patent, #63/375,305 expands the intellectual property related to the company’s development of TRP-8803. About Tryp Therapeutics Tryp Therapeutics is a cutting-edge biotechnology company that is focused on developing molecules related to psilocybin to treat diseases The post Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio appeared first on Psychedelic Chronicle.
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Chronicle
Choose Ketamine Complete Capital Raise to Expand Technology Platform
In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, ha...
Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it ha...
Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has beg...
Latest News
What’s the Deal with the God Molecule?
Here's what you need to know about 5-MeO-DMT [...] Read More... The post What’s the Deal with the God Molecule? appea...
Psychedelic Policy Briefing: Week of July 13th, 2026
Massachusetts advances a psychedelic therapy pilot program, the FDA finalizes its psychedelic trial guidance and sets...
The Rush for Iboga Looks Different from Gabon
Gabonese civil servant and environmental lawyer Georges Gassita on what the ibogaine rush looks like from inside Gabo...
The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet
The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psy...
Do people hear voices when they take ayahuasca? 5 Questions with social anthropologist David Dupuis
Dupuis discusses how auditory hallucinations during psychedelic trips have been overlooked.
One of Psychedelia’s Most Notorious Gurus Is Officially Put on Blast
PLUS, stories about datura, the Huni Kuin, and Oregon's drug policy programs. [...] Read More... The post One of Psyc...